Evaluation of The Effects and Side Effects of Topical Clobetasol 0.05% and Topical Anthralin Treatment in Alopecia Areata with Phototricogram

Yıl 2025, Cilt: 20 Sayı: 1, 13 - 18

Aydan Yazıcı , Şükrü Balevi

https://doi.org/10.17517/ksutfd.1401192

Öz

Objective: Alopecia areata (AA) is a chronic inflammatory disease characterized by non-scarring hair loss. In this study, we aimed to investigate the effects and side effects of topical anthralin and topical clobetasol propionate treatment in patients with AA using a phototrichogram.

Material and methods: The study included 40 patients with AA who were randomly divided into two groups: topical anthralin (n=20) and clobetasol 17-propionate 0.05% (n=20). Phototrichogram values were assessed before and after treatment.

Results: An evaluation of treatment response at the end of three months indicated inadequate response in 7 (35%), partial response in 8 (40%), and cosmetic response in 5 (25%) of the patients in the clobetasol 17-propionate 0.05% group as opposed to inadequate response in 4 (20%), partial response in 8 (40%), and cosmetic response in 8 (40%) of the patients in the local anthralin group. Although the cosmetic response rate was higher in the local anthralin group, there was no significant difference (p=0.470). The rate of patients unresponsive to treatment was lower in the topical anthralin group, while no significant difference was established (p<0.05). In patients whose treatment was not changed throughout the 6 months, cosmetic response was observed in 6 (46.1%) out of 13 (65%) patients who received local clobetasol 17-propionate 0.05% and in 10 (62.5%) out of 16 (80%) patients who received local anthralin and no significant difference was found between the groups (p=0.379). Statistically, treatment success was significantly higher in patients who did not respond to local clobetasol 17-propionate 0.05% treatment and were converted to anthralin treatment than those who underwent a treatment change (p=0.026). On the other hand, at the end of the 6 months, it was revealed that both drugs had no significant effect on the increase in the number of hair follicles per mm2 (NH), hair density (HD), anagen rate (AR), and telogen rate (TR) values (p=0.148).

Conclusion: Topical clobetasol 17 propionate 0.05% lotion and topical anthralin treatment is a safe and effective form of patchy AA treatment. When both drugs were compared, treatment success was statistically superior when switched to topical anthralin treatment in patients who did not respond to topical clobetasol 17 propionate 0.05% lotion. The results of our study and literature reviews indicate the necessity of studies with larger patient series in terms of the effectiveness of these two drugs.

Anahtar Kelimeler

Alopecia areata, topical anthralin, phototricogram, topikal clobetazol

Etik Beyan

Ethics committee approval (No: 2007/070, Date: 25/04/2007) was obtained from Necmettin Erbakan University Meram School of Medicine Ethics Committee

Proje Numarası

204155

Teşekkür

Tez çalşmamda bana desteğini esirgemeyen sayın hocam Şükrü Balevi'ne sonsuz teşekkürelrimi sunarım.

Alopesi Areata'da Fototrikogram ile Topikal Klobetasol 0.05% ve Topikal Antralin Tedavisinin Etki ve Yan Etkisinin Takibi

Öz

Amaç: Alopesia areata (AA) skarsız saç kaybıyla karakterize kronik inflamatuar bir hastalıktır. AA’lı hastalara uygulanan topikal anthralin ve topikal klobetasol propiyonat tedavisinin etki ve yan etkilerini fototikogramla araştırmayı amaçladık.
Gereç ve yöntemler: Alopesia areata’lı 40 hasta çalışmaya alındı ve randomize olarak iki gruba ayrıldı. 20 hasta topikal % 0.05 klobetasol 17 propionat losyon, 20 hasta topikal antralin tedavisi kullandı. Tedavi öncesi ve sonrası değerlendirme fototrikogram ile yapıldı.
Bulgular: Üç ay sonunda tedavi yanıtı değerlendirildiğinde, klobetasol 17-propiyonat %0,05 uygulanan hastaların 7'sinde (%35) yetersiz yanıt, 8'inde (%40) kısmi yanıt, 5'inde (%25) kozmetik yanıt olduğu görüldü. Lokal antralin grubundaki hastaların 4'ünde (%20) yetersiz yanıt, 8'inde (%40) kısmi yanıt, 8'inde (%40) kozmetik yanıt gözlendi. Lokal antralin grubunda kozmetik yanıt oranı daha yüksek olmasına rağmen anlamlı fark yoktu (p=0,470). Topikal antralin grubunda tedaviye yanıt vermeyen hasta oranı daha düşüktü ancak anlamlı fark saptanmadı (p<0,05). Tedavisi 6 ay boyunca değişmeyen hastalarda lokal klobetasol 17-propiyonat %0,05 alan 13 (%65) hastanın 6'sında (%46,1) ve 10 (%62,5) hastada kozmetik yanıt gözlendi. Lokal antralin alan 16 (%80) hastada gruplar arasında anlamlı fark saptanmadı (p=0,379). Lokal klobetasol 17-propiyonat %0,05 tedavisine yanıt vermeyen ve antralin tedavisine geçen hastalarda tedavi başarısı, tedavi değişikliği yapılan diğer hastalara göre istatistiksel olarak anlamlı derecede yüksekti (p=0,026). Öte yandan 6 aylık süre sonunda her iki ilacın da mm2 başına saç kökü sayısı (NH), saç yoğunluğu (HD), anagen oranı (AR) ve telojen oranı (TR) artışına anlamlı bir etkisinin olmadığı ortaya çıktı (p=0,148).
Sonuç: Topikal klobetasol 17 propiyonat %0,05 losyon ve topikal antralin tedavisi, yama tarzı AA tedavisinin güvenli ve etkili bir şeklidir. Her iki ilaç karşılaştırıldığında topikal klobetasol 17 propiyonat %0,05 losyona yanıt vermeyen hastalarda topikal antralin tedavisine geçildiğinde tedavi başarısının istatistiksel olarak üstün olduğu görüldü. Çalışmamızın sonuçları ve literatür taramaları bu iki ilacın etkinliği açısından daha geniş hasta serileri ile çalışmaların gerekliliğini göstermektedir.

Anahtar Kelimeler

alopesi areata, topikal anthralin, fototrikogram, topikal klobetazol

Proje Numarası

204155

Kaynakça

• Braun-Falco O, Plewig G, Wolf HH, Burgdorf WHC. Disease of hair. Dermatology, 2nd ed. Berlin: Springer-Verlag; 2000.p.1099-140.
• Dawber RPR, Berker de D. Disorders of hair. In: Rook A, Wilkinson DS, Ebling FJG (eds.). Textbook of dermatology. 6th ed. Oxford: Blackwell Scientific Publications; 1998. p.2869-973.
• Forslind B. Structure and function of the hair follicle. In: Camacho FM, Randall VA, Price VH, editors. Hair and its disorders. Biology, pathology and management. 1st ed. London, Martin Dunitz Ltd; 2000.p.3-15.
• Sinclair R, Banfield C, Dawber RPR. Handbook of disease of the hair and scalp, Blackwell Science; 1999.p.3-23.
• Hoffmann R. TrichoScan, a GCP-validated tool to measure hair growth. JEADV 2008; 22: 101–136.
• Olsen E, Hordinsky M, Price V, et al. Alopecia areata investigational assessment guidelines–part II. Jaad. 2004;51(3):440-447.
• Messenger A, Mckillop J, Farrant P, McDonagh A, Sladden M. British Association of Dermatologists' guidelines for the management of alopecia Areata 2012. Br J Dermatol. 2012;166(5):916-926.
• Ramos M, Anzai A, Duque-Estrada B, et al. Consensus on the treatment of alopecia areata – Brazilian society of dermatology. An Bras Dermatol. 2020;95:39-52
• Nassar A, Elradi M, Radwan M, Albalat W. Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study. J Cosmet Dermatol. 2023;22:1297-1303.
• Ucak H, Kandi B, Cicek D, Halisdemir N, Dertlioğlu SB. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatol Treat. 2012;23:6, 410-420.
• Schmoeckel C, Weissmann I, Plewig G, Braun Falco O. Treatment of alopecia areata by anthralin‐induced dermatitis. Arch Dermatol. 1979;115(10):1254‐1255
• Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol. 2014;53(10):e449‐e460.
• Özdemir M, Balevi A. Bilateral half‐head comparison of 1% anthralin ointment in children with alopecia areata. Pediatr Dermatol. 2017;34 (2):128‐132
• Hordinsky MK. Overview of alopecia areata. J Investig Dermatol Symp Proc 2013;16:S13–5.
• Nelson DA, Spielvogel RL. Anthralin therapy for alopecia areata. Int J Derm 1985;24: 606-7.
• Fiedler-Weiss V, Buys C. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123:1491-3.
• Wu SZ, Wang S, Ratnaparkhi R, Bergfeld WF. Treatment of pediatric alopecia areata with anthralin: A retrospective study of 37 patients. Pediatr Dermatol. 2018;35:817–820.
• Durdu M, Özcan D, Baba M, Seçkin D. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series. J Am Acad Dermatol. 2015;72:640–50.
• Nasimi M, Ghandi N, Abedini R, Mirshamsi A, Shakoei S, Seirafi H. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: A retrospective case series. Arch Dermatol Res. 2019;311:607–13.
• Saşmaz Sezai, Arıcan Ö. Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata. Am J Clin Dermatol 2005;6:403-6.
• Fiedler VC, Wendrow A, Szpunar GJ et al. Treatment of resistant alopecia areata. Arch Dermatol 1990;126:756
• Bolduc C, Shapiro J. The treatment of alopecia areata. Dermatologic Therapy 2001;14:306- 16.
• Charuwichitratana S. Randomized double-blind placebo-conrolled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 2000;136:1276-7
• Mancuso G, Balducci A, Casadio C, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to- moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator- blinded trial. Int J Dermatol 2003;42:572–5.
• Fiedler VC: Alopecia areata: A review of therapy, effıcacy, safety and mechanism. Arch Dermatol 1992;128:1519
• Rokhsar CK, Shupack J L, Vafai J J, Washenik K: Efficacy of topical sensitizers in treatment of alopecia areata. J Am Acad Dermatol 1998; 39:751-61.
• White SI, Friedmann PS. Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol 1985;121:591.
• Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate %0.05 foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20:1243-7.